Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;7(1):105-119.
doi: 10.1007/s40122-017-0092-3. Epub 2017 Dec 1.

Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis

Vasiliki Brozou  1 , Athina Vadalouca  2 , Panagiotis Zis  3
Affiliations
Review

Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis

Vasiliki Brozou et al. Pain Ther. 2018 Jun.

Abstract

Introduction: Platin-induced peripheral neuropathy (PIPN) is a common cause of PN in cancer patients. The aim of this paper is to systematically review the current literature regarding PIPN, with a particular focus on epidemiological and clinical characteristics of painful PIPN, and to discuss relevant management strategies.

Methods: A systematic computer-based literature search was conducted on the PubMed database.

Results: This search strategy resulted in the identification of 353 articles. After the eligibility assessment, 282 articles were excluded. An additional 24 papers were identified by scanning the reference lists. In total, 95 papers met the inclusion criteria and were used for this review. The prevalence of neuropathic symptoms due to acute toxicity of oxaliplatin was estimated at 84.6%, whereas PN established after chemotherapy with platins was estimated at 74.9%. Specifically regarding pain, the reported prevalence of pain due to acute toxicity of oxaliplatin was estimated at 55.6%, whereas the reported prevalence of chronic peripheral neuropathic pain in PIPN was estimated at 49.2%.

Conclusion: Peripheral neuropathy is a common complication in patients receiving platins and can be particularly painful. There is significant heterogeneity among studies regarding the method for diagnosing peripheral neuropathy. Nerve conduction studies are the gold standard and should be performed in patients receiving platins and complaining of neuropathic symptoms post-treatment.

Keywords: Cancer; Chemotherapy; Pain; Platin; Polyneuropathy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA chart
See this image and copyright information in PMC

References

    1. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62(4):310–318. - PMC - PubMed
    1. Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol. 2016;263(10):1903–1910. - PubMed
    1. Zis P, Varrassi G. Painful peripheral neuropathy and cancer. Pain Ther. 2017 - PMC - PubMed
    1. Marchettini P, Formaglio F, Lacerenza M. Iatrogenic painful neuropathic complications of surgery in cancer. Acta Anaesthesiol Scand. 2001;45(9):1090–1094. - PubMed
    1. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967. - PubMed